A celebration of innovation in UK pharma.
By 2018 the pharma industry will become the single biggest source of global R&D. It already accounts for 48% of national R&D spend in the UK. Other than the US, Britain has developed more medicines than any other country. Prix Galien rewards that investment in innovation. Here’s why…
Changing clinical practice.
Prix Galien’s Innovative Product Award recognises UK pharma’s ongoing efforts to curb disease and improve public health. New medicines that have launched or been granted a new indication in the UK in the 2-year qualifying period are eligible for entry. For entry details, including key dates and processes, click here.